November 19, 2026 · Pharmaceuticals
FDA's Global Reliance Disclosure Program and Health Canada Submissions
By Mussarat Fatima

On 17 November 2026, the United States Food and Drug Administration announced the Global Reliance Disclosure Program, or GRDP. Under it, the FDA shares minimally redacted approval packages, including its detailed scientific and regulatory assessments, directly with companies, who can then share them with regulatory authorities outside of the United States. The aim is to let foreign regulators rely on the FDA's review rather than repeat the full evaluation themselves.
For a Canadian sponsor, this is a quiet but important change in how a drug or biologic can reach more than one market. If you are approved by the FDA and you plan to file the same product with Health Canada or another regulator, you may now be able to hand that regulator the FDA's own assessment to support a reliance based review. There is a catch that matters: you have to ask the FDA to participate within a tight window after approval, so this becomes a planning step, not an afterthought.
This article explains what the GRDP is, exactly what the FDA shares and when, who can use it today, what is planned for 2027, and the practical steps Canadian sponsors should build into their submission strategy. Every fact here comes from the FDA's own press release, which is linked in the sources at the end. GRDP is an FDA disclosure program. It does not bind Health Canada or any other regulator to rely on an FDA decision. Each regulator still decides for itself.
Executive Summary
Reliance, where one regulator uses another's review to reach its own decision faster, is becoming a central feature of global drug regulation. The GRDP is the FDA's contribution to that trend on the disclosure side. Instead of a foreign regulator asking for an FDA assessment, the applicant can obtain a minimally redacted version of the FDA's approval package and provide it directly, so the foreign regulator can lean on the FDA's work while keeping full control of its own decision.
The practical significance for Canadian sponsors is twofold. First, a product approved by the FDA now carries a shareable, officially disclosed assessment that can support a reliance based Health Canada review, which can shorten timelines when it works. Second, the 10 calendar day request window turns FDA approval into a moment that requires a decision and an action, not just a celebration. Miss the window and you may lose the easiest route to that package. Building this into your regulatory plan is the real takeaway.
What is the Global Reliance Disclosure Program?
In short: The GRDP is an FDA program, announced on 17 November 2026, under which the FDA shares minimally redacted approval packages, including its detailed scientific and regulatory assessments, directly with applicants. Those applicants can then give the packages to regulatory authorities outside the United States so those regulators can rely on the FDA's science based review decisions while keeping sovereignty over their own decision.
The FDA frames the program as a way for foreign regulators to avoid, in the agency's words, duplicative and time consuming product evaluations of their own. Grace Graham, the FDA Deputy Commissioner for Policy, Legislation, and International Affairs, described the GRDP as making it easier for applicants to leverage the agency's detailed scientific assessments to facilitate faster access for patients everywhere. Mark Abdoo, Associate Commissioner for Global Policy and Strategy, said the FDA's leadership is most effective when it is collaborative and defined by a willingness to share expertise.
One point is worth stating plainly, because it is easy to overread an announcement like this. The GRDP changes what the FDA will disclose. It does not change what any other regulator must do. Health Canada, the EMA, the MHRA, and others each run their own reliance policies and will decide case by case whether and how to use an FDA package. The GRDP simply makes a credible, officially disclosed FDA assessment available for you to put in front of them.
What the FDA shares, and what it does not
In short: The FDA shares a minimally redacted version of the approval package, including its detailed scientific and regulatory assessments. Requests made for other purposes, rather than to support a foreign marketing application, are not handled under the GRDP and should go through a Freedom of Information Act request instead.
The value of the package is that it is the FDA's own assessment, lightly redacted, rather than a summary prepared by the applicant. That is what gives it weight with another regulator. The FDA says applicants will receive detailed information in their FDA approval letters and that the agency intends to provide the minimally redacted package on an expedited basis once a valid request is made. The FDA has not published a public list of exactly what is removed in redaction, so treat the precise contents as something to confirm with the agency for your specific product.
The 10 day window: a new step at FDA approval
In short: To use the GRDP, an applicant must request to participate within 10 calendar days of approval and confirm that the application package is being submitted to a foreign regulatory authority in support of a marketing application. This makes participation a time critical action tied to the approval date, not something you can arrange months later.
| Step | What the applicant must do | Why it matters |
|---|---|---|
| At approval | Watch for the detailed GRDP information in the FDA approval letter | The clock starts at approval, so the approval letter is the trigger to act on |
| Within 10 calendar days | Request to participate in the GRDP | Miss the window and the easy, expedited route to the package may close |
| With the request | Confirm the package will go to a foreign regulator in support of a marketing application | GRDP is only for supporting a foreign marketing application, not for general disclosure |
| Other purposes | Use a Freedom of Information Act request instead | Requests outside the GRDP purpose are not processed under the program |
For a Canadian sponsor, the lesson is simple. By the time the FDA approves your product, you should already know whether you intend to file it with Health Canada or another regulator, and you should have someone ready to lodge the GRDP request inside the 10 day window. That means the decision belongs in your submission plan long before approval, alongside the rest of your international reliance strategy.
Who can use it now, and what is coming in 2027
In short: Today the GRDP is narrow. It launched on 30 October and is currently available only for PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products. The FDA intends to widen it in January 2027 to all novel drugs and biologics, and to add a pathway in early 2027 for products that are already approved or licensed.
| Phase | Scope | Status |
|---|---|---|
| Launch, 30 October 2026 | PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products | In effect now |
| January 2027 (intended) | All novel drugs and biologics: New Molecular Entity New Drug Applications and 351(a) Biologics License Applications | Announced as intended, not yet in force |
| Early 2027 (intended) | A pathway for drugs and biologics that are already approved or licensed to request their packages | Announced as intended, not yet in force |
The January 2027 expansion is the one most Canadian sponsors should watch, because it brings new drugs and new biologics into scope. A New Molecular Entity New Drug Application is the application type for a genuinely new small molecule drug, and a 351(a) Biologics License Application is the standalone application for a new biologic. In plain terms, if you are bringing a new product to market and the FDA approves it, you may soon be able to carry the FDA's assessment into your Health Canada or other foreign filings. Because these dates are stated as the FDA's intent, confirm the program is actually in force for your product type before you build it into a binding timeline.
Why this matters for Health Canada submissions
In short: Health Canada already has its own reliance framework, and an officially disclosed FDA assessment is exactly the kind of foreign review that a reliance based pathway is designed to use. The GRDP gives Canadian sponsors a cleaner, faster way to obtain that FDA material, which can support a quicker Canadian review when Health Canada chooses to rely.
Canada has been moving steadily toward reliance. The Ministerial Reliance Order lets Health Canada rely on decisions and documents from comparable foreign regulators for certain drugs, and we have written about the broader Foreign Reliance Order and how to qualify for it. The GRDP fits neatly into that world. If Health Canada is willing to rely on the FDA for your product, a minimally redacted FDA assessment in your hands is a strong, officially sourced input to that review.
The caution is the same one that applies to all reliance. Health Canada decides whether to rely, on which elements, and to what degree. Reliance is not automatic recognition. Your Canadian file still has to stand on its own, with Canadian specific requirements such as bilingual labelling, a Canadian product monograph, and local quality and pharmacovigilance commitments. The FDA package supports the review. It does not replace your submission.
How reliance already works, and where GRDP fits
In short: Reliance lets a regulator use another regulator's work to reach its own decision faster, without surrendering authority. The GRDP is a disclosure mechanism that feeds reliance by making the FDA's assessment easy to share. It sits upstream of the foreign regulator's decision, not in place of it.
Think of two separate questions. The first is whether you can obtain the FDA's assessment to share. That is what the GRDP answers, and the 10 day window is the gate. The second is whether a given regulator will actually rely on it, and how much. That is governed by that regulator's own reliance policy, the product type, and the completeness of your local file. A strong submission strategy manages both: it captures the FDA package through the GRDP and it prepares each foreign file so the regulator can rely with confidence. The same discipline that supports a clean dossier, from validated manufacturing to a defensible stability programme and sound supplier qualification, is what makes a reliance review go smoothly.
Steps Canadian sponsors should take now
- Map your multi market plan before FDA approval. Decide early which products you will file with Health Canada or other regulators, so a GRDP request is a planned action, not a scramble after approval.
- Assign an owner for the 10 day window. Name the person responsible for spotting the GRDP information in the FDA approval letter and lodging the request within 10 calendar days. Put it in your approval checklist.
- Confirm the program covers your product type. Today the GRDP is limited to certain PEPFAR tentative approvals. Before you rely on the January 2027 or early 2027 expansions, confirm they are actually in force for your New Molecular Entity application or your 351(a) biologic.
- Align your Health Canada strategy with reliance. Understand where Health Canada can rely on an FDA decision and build your Canadian file so it supports reliance, including Canadian labelling, a product monograph, and local commitments.
- Keep your quality and clinical records reliance ready. A reliance review still tests the strength of your dossier. Keep your stability, validation, and clinical disclosure obligations current and consistent across markets.
GRDP readiness checklist
- Your regulatory plan states, before FDA approval, which products will be filed with Health Canada or other foreign regulators.
- A named owner is responsible for requesting GRDP participation within 10 calendar days of FDA approval.
- Your approval checklist includes checking the FDA approval letter for GRDP information.
- You have confirmed whether your product type is currently eligible, rather than assuming the 2027 expansions are already in force.
- Your Canadian submission is built to support, not replace, a reliance based review, with bilingual labelling and a product monograph in hand.
- Your quality, stability, and pharmacovigilance records are consistent across every market you file in.
Common mistakes to avoid
- Treating GRDP as automatic approval abroad. A shared FDA package supports a foreign review. It does not guarantee that Health Canada or any regulator will rely on it or approve your product.
- Missing the 10 day window. The request is tied to the approval date. If no one is watching for the approval letter, the easy route to the package can close before you act.
- Assuming the 2027 scope is live now. The January and early 2027 expansions are stated as the FDA's intent. Confirm they are in force before you plan around them.
- Neglecting the Canadian specific file. Reliance does not remove Canadian requirements such as bilingual labelling, a product monograph, and local commitments. The foreign package is an input, not a substitute.
- Using GRDP for the wrong purpose. The program is for supporting a foreign marketing application. Other disclosure needs go through a Freedom of Information Act request, not the GRDP.
Frequently Asked Questions
What is the FDA Global Reliance Disclosure Program?
The GRDP is an FDA program announced on 17 November 2026. Under it, the FDA shares minimally redacted approval packages, including its detailed scientific and regulatory assessments, directly with applicants, who can then share them with regulators outside the United States to support reliance based reviews.
What does the FDA share under the GRDP?
The FDA shares a minimally redacted version of the approval package, including its detailed scientific and regulatory assessments. The FDA says applicants will receive detailed information in their approval letters and that it intends to provide the package on an expedited basis after a valid request.
How long do I have to request participation?
An applicant must request to participate within 10 calendar days of approval and confirm that the package is being submitted to a foreign regulatory authority in support of a marketing application. Requests for other purposes should go through a Freedom of Information Act request instead.
Who can use the GRDP right now?
At launch on 30 October, the program is available only for PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products. The FDA intends to widen it in 2027.
When will the GRDP expand to new drugs and biologics?
The FDA has stated it intends to expand the program in January 2027 to all novel drugs and biologics, meaning New Molecular Entity New Drug Applications and 351(a) Biologics License Applications, and to add a pathway in early 2027 for products already approved or licensed. These dates are stated as intent, so confirm the program is in force for your product before planning around it.
Does the GRDP mean Health Canada will automatically accept an FDA approval?
No. The GRDP is an FDA disclosure program. It makes the FDA's assessment available to share. Health Canada decides independently, under its own reliance framework, whether and how to rely on an FDA decision. Your Canadian file still has to meet Canadian requirements.
How does the GRDP fit with Health Canada's reliance pathways?
Health Canada can rely on decisions and documents from comparable foreign regulators under its reliance framework. A minimally redacted FDA assessment obtained through the GRDP is exactly the kind of foreign review that can support such a reliance based Canadian review, when Health Canada chooses to rely.
How MFLRC Can Help
MF License and Regulatory Consultants helps Canadian and international sponsors turn a strong FDA outcome into faster access in other markets. Our President, Mussarat Fatima, is a Health Canada security cleared, approved Quality Assurance Person with more than twenty years in regulatory affairs and quality across pharmaceuticals, biologics, natural health products, and food.
For reliance and submission strategy, we offer multi market regulatory planning, Health Canada submission and reliance pathway support, dossier and quality readiness reviews, licensing and import and export compliance, and ongoing regulatory intelligence so you are never surprised by a change like the GRDP. We help you capture the FDA package in time and build Canadian filings that a regulator can rely on with confidence.
Planning a multi market launch, or an FDA approval you also want to file in Canada? Book a consultation and we will map your reliance strategy, including how and when to use the GRDP.
Conclusion
The Global Reliance Disclosure Program reflects where global regulation is heading. Regulators increasingly want to rely on each other's work, and the GRDP makes the FDA's assessment easy to share so they can. For Canadian sponsors, the opportunity is real, but it comes with a deadline. The FDA package can smooth a reliance based Health Canada review, yet only if you request it within 10 calendar days of approval and only if your Canadian file is built to support reliance rather than lean on it entirely. Plan for the window, build the local file properly, and treat the GRDP as one well timed input into a strategy you still own. MFLRC can help you put that strategy in place.
Sources and References
Downloadable Resource
FDA GRDP and Health Canada Reliance Readiness Checklist
A one page checklist to plan your FDA Global Reliance Disclosure Program request and build Health Canada filings that support a reliance based review.
File: MFLRC-FDA-GRDP-Reliance-Readiness-Checklist.pdf
Share with others
Tags
